Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
10 Juin 2023 - 7:00AM
Business Wire
- IPH6501 is a first-in-class tetra-specific antibody-based
natural killer cell engager therapeutic, based on ANKET® platform,
targeting CD20 developed for the treatment of B-cell non-Hodgkin's
lymphomas
- IPH6501 is progressing towards a Phase 1 clinical trial in
2023
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that
updated preclinical data on its IPH6501 tetra-specific ANKET®
(Antibody-based Natural Killer cell
Engager Therapeutics) are presented at the European
Hematology Association (EHA) 2023 congress. IPH6501 is a
first-in-class CD20-targeting tetra-specific ANKET® that co-engages
two activating receptors (NKp46 and CD16), the interleukin-2
receptor (without involvement of the IL-2Rα subunit) with a human
IL-2 variant and CD20 target antigen on malignant B cells.
In preclinical settings, IPH6501 was shown to induce NK cell
proliferation and to trigger high NK cell cytoxicity against CD20+
target cells in in vitro assays, in ex vivo assays with
relapse/refractory (R/R) B-NHL patient samples who received at
least one prior treatment, as well as in in vivo studies in
non-human primates. A surrogate of IPH6501 mediated a potent
anti-tumor activity in vivo in CD20+ tumor models in mice. In
addition, in ex vivo assays with R/R B-NHL patient samples, IPH6501
was shown to be more efficient than a T cell engager targeting
CD20.
Pr. Eric Vivier, PhD, DVM, Chief Scientific Officer at Innate
Pharma “As the lead in this new class of tetra-specific NK-cell
engager, IPH6501 represents an innovative option for the treatment
of R/R B-cell non-Hodgkin’s lymphomas after multiple lines of
treatment, who are still in need of therapies. By providing
proliferation and activation signals targeted to NK cells, the
tetra-specific NK Cell Engager based on our ANKET® platform
leverages the advantages of harnessing NK cell effector functions
against cancer cells. With a low systemic cytokine release profile,
IPH6501 represents a promising alternative strategy to T cell
therapies. IPH6501 continues to progress towards a Phase 1 clinical
trial and we look forward to share further updates on other ANKET®
assets as they enter clinic.”
About ANKET®
ANKET® is Innate’s proprietary platform for developing
next-generation, multi-specific natural killer (NK) cell engagers
to treat certain types of cancer. This fit-for-purpose technology
is creating an entirely new class of molecules to induce synthetic
immunity against cancer.
Innate’s latest innovation, the tetra-specific ANKET®, is the
first NK cell engager technology to engage activating receptors
(NKp46 and CD16), a tumor antigen and the interleukin-2 receptor
(via an non-alpha IL-2 variant, IL-2v) via a single molecule. By
providing proliferation and activation signals targeted to NK
cells, tetra-specific ANKET® leverages the advantages of harnessing
NK cell effector functions against cancer cells.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on Twitter and LinkedIn.
Information about Innate Pharma shares
ISIN code
FR0010331421
Ticker code
Euronext: IPH Nasdaq: IPHA
LEI
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2022,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230609005396/en/
Investors
Innate Pharma Henry Wheeler Tel.: +33 (0)4 84 90
32 88 Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024